

BIOSANTE PHARMACEUTICALS INC  
Form 8-K  
January 06, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported):  
**January 4, 2005**

**BIOSANTE PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**                                      **1-31812**                                      **58-2301143**  
(State or other jurisdiction of      (Commission File Number)      (I.R.S. Employer Identification  
incorporation)                                      Number)

**111 Barclay Boulevard**  
**Lincolnshire, Illinois**                                      **60069**  
(Address of principal executive offices)                                      (Zip Code)

**(847) 478-0500**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Section 1 Registrant's Business and Operations**

**Item 1.01 Entry into a Material Definitive Agreement**

On January 4, 2005, BioSante Pharmaceuticals, Inc. entered into a Second Amendment to the Lease with LaSalle Bank National Association, as successor trustee to American National Bank and Trust Company of Chicago effective as of January 4, 2005. The Second Amendment amends the Lease, dated as of December 19, 2003, as amended, between BioSante and LaSalle Bank National Association. The Amendment is filed as Exhibit 10.1 to this report and is incorporated herein by this reference.

The Amendment, among other things, extends the term of the Lease, as amended, from March 21, 2005 to March 31, 2006. The annual base rent remains the same at approximately \$88,400.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits. The following exhibit is filed herewith:

<b>Exhibit No.</b>	<b>Description</b>
10.1	Second Amendment to Lease dated as of January 4, 2005, by and between BioSante Pharmaceuticals, Inc. and LaSalle Bank National Association, as successor trustee to American National Bank and Trust Company of Chicago.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: /s/Phillip B. Donenberg  
*Chief Financial Officer, Treasurer and Secretary*

Dated: January 6, 2005

---

**BIOSANTE PHARMACEUTICALS, INC.**  
**FORM 8-K**  
**EXHIBIT INDEX**

**Exhibit No.**   **Description**

10.1            Second Amendment to Lease dated as of January 4, 2005, by and between BioSante Pharmaceuticals, Inc. and LaSalle Bank National Association, as successor trustee to American National Bank and Trust Company of Chicago.